SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in February 2026 and will also participate in one-on-one investor meetings at each of these conferences.
Guggenheim Emerging Outlook: Biotech Summit 2026 (February 11-12, 2026)
Location: New York, NY
Format: Fireside Chat
Date and Time: Thursday, February 12, 1:00 pm Eastern Time
Oppenheimer 36th Annual Healthcare Life Sciences Conference (February 25-26, 2026)
Location: Virtual
Format: Fireside Chat
Date and Time: Thursday, February 26, 11:20 am Eastern Time
A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Comments